ArticleBMC psychiatry2025
Research on the correlation of nitric oxide-induced neuronal cell pyroptosis with schizophrenia and its cognitive impairment.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSchizophrenia (SZ) is a severe mental illness that significantly impairs patients' quality of life and cognitive functioning.
objectiveThis study investigates the role of nitric oxide (NO) in SZ pathogenesis by examining its induction of neuronal pyroptosis and its correlation with cognitive impairment. We aimed to identify potential therapeutic targets by analyzing the expression of pyroptosis-related genes (NLRP3, Caspase-1, GSDMD), inflammatory factors (IL-1β, IL-18), and SZ susceptibility genes (CUX2, DTNBP1).
methods(1) SH-SY5Y cells were treated with sodium nitroprusside (NO donor) at varying concentrations. Cell viability, NO levels, and gene expression were assessed using Cell Counting Kit-8(CCK-8), Griess reagent, and qPCR assays. (2) Clinical analysis included 58 SZ patients and 62 healthy controls. Cognitive function was evaluated using RBANS, and NO levels and gene expression were measured in blood samples.
results(1) NO treatment reduced SH-SY5Y cell viability and altered the expression of pyroptosis-related and susceptibility genes, and the IC50 value of sodium nitroprusside on SH-SY5Y cells was 1.4 mM. (2) SZ patients exhibited elevated NO levels, reduced cognitive scores, and dysregulated gene expression compared to controls. NLRP3 and IL-18 were strongly associated with cognitive impairment.
conclusionNO serves an essential role in the pathological mechanisms of schizophrenia by inducing neuronal pyroptosis, potentially through the key factor NLRP3. Additionally, NLRP3 and IL-18 are strongly linked with cognitive impairment in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.